In this conversation, Sapna Patel and James Larkin discuss the EORTC 18071 study, which compared adjuvant ipilimumab to placebo in patients with stage III melanoma. They explore the use of adjuvant interferon in the past and the controversies surrounding its overall survival benefit. They also discuss the tolerability and side effects of ipilimumab, as well as the potential reasons for the survival benefit seen in the EORTC 18071 study. The conversation concludes with a summary of the study's findings.

Keywords

adjuvant therapy, ipilimumab, placebo, stage three melanoma, EORTC 18071 study, adjuvant interferon, overall survival benefit, tolerability, side effects, survival benefit

Takeaways

The EORTC 18071 study showed a significant overall survival benefit with adjuvant ipilimumab in patients with stage three melanoma.

The use of adjuvant interferon in the past was controversial, with a loss of overall survival benefit over time.

Ipilimumab has significant side effects and can impact patients' quality of life.

The survival benefit seen in the EORTC 18071 study may be due to the early use of CTLA-4 blockade in the immune sequence.

The subsequent use of PD-1 therapy as salvage treatment may explain the lack of overall survival benefit in other checkpoint inhibitor adjuvant trials.

Titles

Potential Reasons for Survival Benefit in the EORTC 18071 Study

Tolerability and Side Effects of Ipilimumab in Adjuvant Therapy

Sound Bites

"This was our only study that actually has overall survival benefit in the adjuvant setting using checkpoint inhibitor."

"The use of adjuvant interferon really dwindled when that OS benefit was lost."

"We would tell patients, you will know you're on treatment and you will walk around feeling like you have the flu."

Chapters

00:00 Introduction and Quick Fire Questions

02:05 Overview of the EORTC 18071 Study

06:11 Tolerability and Side Effects of Ipilimumab

11:06 Potential Reasons for Survival Benefit in EORTC 18071 Study

14:25 Wrap-up of Ipilimumab Discussion